Cystic Fibrosis Summary

Overview of Cystic Fibrosis (CF)

  • Genetic disorder caused by mutations in the CFTR gene.

  • Most prevalent life-limiting genetic disorder in Caucasians.

  • Leads to thick secretions impacting multiple organs: lungs, pancreas, liver, intestines, sinuses, skin.

  • Primary cause of death: progressive lung disease causing respiratory failure.

  • Diagnosed through newborn screening (NBS) required in all states.

Genetics

  • CF is autosomal recessive; both parents must carry mutations.

  • ΔF508 mutation is most common among northern European ancestry.

Pathophysiology

  • CFTR protein functions as a chloride channel; its dysfunction disrupts ion transport, causing viscous secretions.

  • Potential therapies include correctors, potentiators, and gene editing techniques.

Clinical Presentation

  • Multi-systemic effects:

  • Lungs: bronchiectasis, frequent infections.

  • GI tract: pancreatic insufficiency, diabetes, constipation (DIOS).

  • Sinuses: nasal polyps, chronic congestion.

  • Reproductive: congenital absence of vas deferens in males.

Complications and Treatments

  • Pancreatic Complications:

  • 90% have pancreatic insufficiency.

  • Treatment: Pancreatic Enzyme Replacement Therapy (PERT).

  • Respiratory Complications: Primary concern; 90% of CF fatalities due to lung issues.

  • Management: bronchodilators, mucolytics, antibiotics.

Pharmacologic Management**

Pharmacologic Management of Cystic Fibrosis

  • CFTR Modulators: These are targeted therapies designed to address the specific genetic defect in the CFTR gene that causes cystic fibrosis. By improving the function of the CFTR protein, they help to reduce the severity of symptoms and improve the quality of life for patients. Examples include:

  • Kalydeco® (Ivacaftor): Specifically indicated for patients with certain mutations in the CFTR gene, particularly those that lead to the gating defect of the protein. Clinical studies have shown significant improvements in lung function and a reduction in pulmonary exacerbations in eligible patients.

  • Orkambi® (Lumacaftor/Ivacaftor): Approved for patients aged 12 years and older who are homozygous for the ΔF508 mutation.

  • Symdeko® (Tezacaftor/Ivacaftor): A newer therapy for patients aged 12 and older, effective for those with specific mutations, including ΔF508.

  • Trikafta® (Elexacaftor/Tezacaftor/Ivacaftor): A breakthrough therapy available for individuals aged 12 and older who have at least one ΔF508 mutation.

  • Monitoring: Patients on CFTR modulators require regular monitoring for liver function, specifically testing the levels of AST (aspartate aminotransferase) and ALT (alanine aminotransferase), as elevated liver enzymes can signal potential liver damage. Additionally, healthcare providers must be vigilant regarding possible drug-drug interactions, particularly with CYP3A4 inhibitors/inducers, which can alter the metabolism of these medications and affect their efficacy and safety.

  • Kalydeco® - Ivacaftor

  • Orkambi® - Lumacaftor/Ivacaftor

  • Symdeko® - Tezacaftor/Ivacaftor

  • Trikafta® - Elexacaftor/tezacaftor/ivacaftor

  • Regular monitoring for liver function (AST/ALT) and drug-drug interactions (CYP3A4 inhibitors/inducers).

Important Takeaways

  • CF is an ongoing management condition affecting multiple systems.

  • Emphasis on multidisciplinary care to handle complex manifestations.

  • New therapies are improving life expectancy significantly compared to historical averages.